Spero Therapeutics, Inc.

Total Valuation

Spero Therapeutics, Inc. carries a market capitalization of 70.06M, placing it among publicly traded companies globally. Its enterprise value stands at 79.77M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Spero Therapeutics, Inc. currently has 58.15M shares outstanding.

Valuation Ratios

Spero Therapeutics, Inc. trades at a trailing price-to-earnings ratio of 17.03. The price-to-sales ratio is 2.93, and the price-to-book ratio stands at 2.91.

Enterprise Valuation

On an enterprise value basis, Spero Therapeutics, Inc. trades at an EV/EBITDA multiple of 12.06 and an EV/FCF ratio of 4.07. The EV/Sales ratio of 1.86 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 12.06 provides insight into valuation relative to core operating earnings.

Financial Position

Spero Therapeutics, Inc. maintains a current ratio of 6.12, meaning it holds 6.1x the short-term assets needed to cover near-term liabilities.

Financial Efficiency

Spero Therapeutics, Inc. posts a return on equity of 19.17 and a return on invested capital of 15.39.

Taxes

Over the trailing twelve months, Spero Therapeutics, Inc. has paid 261,000.00 in income taxes, reflecting an effective tax rate of 3.41.

Stock Price Statistics

Spero Therapeutics, Inc.'s stock has declined approximately -39.5% over the past 52 weeks. The 50-day moving average sits at 1.47, while the 200-day moving average is 2.22.

Income Statement

Over the trailing twelve months, Spero Therapeutics, Inc. generated 42.96M in revenue and converted that into 7.38M in net income, yielding earnings per share of 0.13. EBITDA reached 6.61M, while operating income came in at 6.61M.

Balance Sheet

Spero Therapeutics, Inc. holds 50.77M in cash and equivalents against 2.04M in total debt, resulting in a net debt position of -50.77M. Total book value stands at 44.20M, with working capital of 43.16M providing operational flexibility.

Cash Flow

Spero Therapeutics, Inc. produced 19.58M in operating cash flow over the past twelve months.

Margins

Spero Therapeutics, Inc. operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of 15.39 and net profit margin of 17.18 provide insight into operational efficiency.

Dividends & Yields

Scores

Spero Therapeutics, Inc. posts an Altman Z-Score of -1.20, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.